SCHEMBL2280459

SCHEMBL2280459

COCCOC(=O)Nc1cccc(/C=C/C(=O)c2c(O)cc(C)n(C)c2=O)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.48
NPC1 O15118 1/20 0.48
MAPT P10636 2/20 0.39
NPSR1 Q6W5P4 2/20 0.39
ABCG2 Q9UNQ0 1/20 0.38
MMP1 P03956 3/20 0.38
MMP2 P08253 3/20 0.38
MMP9 P14780 3/20 0.38
CYP19A1 P11511 1/20 0.38
CYP2C9 P11712 1/20 0.38
MAOA P21397 1/20 0.38
MAOB P27338 1/20 0.38
CYP2C19 P33261 1/20 0.38
KDM1A O60341 1/20 0.36
ABCB1 P08183 2/20 0.36
MEN1 O00255 1/20 0.36
PSMD14 O00487 1/20 0.36
LMNA P02545 1/20 0.36
GAA P10253 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2280461 1.00 RAB9A (0.48) RAB9ANPC1MAPTNPSR1ABCG2
SCHEMBL2279989 0.90 NPSR1 (0.40) RAB9ANPC1MAPTNPSR1ABCG2
SCHEMBL2279991 0.90 NPSR1 (0.40) RAB9ANPC1MAPTNPSR1ABCG2
SCHEMBL2279274 0.86 NPC1 (0.48) RAB9ANPC1MAPTNPSR1ABCG2
SCHEMBL12374658 0.86 NPC1 (0.48) RAB9ANPC1MAPTNPSR1ABCG2
SCHEMBL2277182 0.84 HDAC3 (0.50) RAB9ANPC1MAPTNPSR1ABCG2
SCHEMBL2277187 0.84 HDAC3 (0.50) RAB9ANPC1MAPTNPSR1ABCG2
SCHEMBL2275832 0.84 NPC1 (0.50) RAB9ANPC1MAPTNPSR1ABCG2
SCHEMBL2275829 0.84 NPC1 (0.50) RAB9ANPC1MAPTNPSR1ABCG2
SCHEMBL13402966 0.83 NPC1 (0.38) RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989478-B2 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-02 US disclosed
US-7989478-B2 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-02 US disclosed
US-7989478-B2 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-02 US disclosed
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-09-21 US disclosed
EP-1671948-A1 CINNAMOYL COMPOUND AND USE OF THE SAME Sumitomo Chemical Company, Limited (JP) 2006-06-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis COL2A1, COL1A1, COL14A1 RAB9A 3791/4885NPC1 1610/4885MAPT 4848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.